NCT03411161: S 81694 Plus Paclitaxel in Metastatic Breast Cancer

NCT03411161
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: All metastatic breast cancer patients are eligible for phase 1; Only triple negative breast cancer patients are also eligible for Ph+ase 2
Exclusions: Unstable brain or leptomeningeal metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT03411161

Comments are closed.

Up ↑